Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy

[1]  L. Esserman,et al.  Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis , 2020 .

[2]  A. Soran,et al.  Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy , 2019, Advances in radiation oncology.

[3]  M. Gnant,et al.  Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial , 2018, Trials.

[4]  V. Caron,et al.  United states. , 2018, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[5]  D. Voduc,et al.  Neoadjuvant systemic therapy in breast cancer: use and trends in radiotherapy practice. , 2017, Current oncology.

[6]  H. Kuerer,et al.  Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members , 2017, Annals of Surgical Oncology.

[7]  H. Kuerer,et al.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Hortobagyi,et al.  Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. , 2016, JAMA oncology.

[9]  J. Haukoos,et al.  The Propensity Score. , 2015, JAMA.

[10]  C. Gross,et al.  Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States , 2015, Cancer.

[11]  H. Kuerer,et al.  Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). , 2015, Annals of surgery.

[12]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[14]  S. Mclaughlin,et al.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. , 2013, JAMA.

[15]  G. Hortobagyi,et al.  10-year outcomes of breast cancer patients with histologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. , 2013 .

[16]  Stewart J Anderson,et al.  Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Marie Davidian,et al.  Doubly robust estimation of causal effects. , 2011, American journal of epidemiology.

[18]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[19]  R. Rosenfeld,et al.  Cases , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[20]  DeAnn Lazovich,et al.  Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Austin.  Goodness‐of‐fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score , 2008, Pharmacoepidemiology and drug safety.

[22]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[23]  G. Tienhoven,et al.  Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: the MRC/EORTC SUPREMO trial. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  Kelly K Hunt,et al.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Rubin,et al.  Fully conditional specification in multivariate imputation , 2006 .

[26]  M. Wexler.  Role of axillary lymph-node dissection in the management of breast cancer. , 2003, Canadian journal of surgery. Journal canadien de chirurgie.

[27]  F. Penault-Llorca,et al.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.

[28]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[29]  G. Murphy,et al.  Management and survival of female breast cancer: Results of a national survey by the American college of surgeons , 1980, Cancer.

[30]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .